Enfusion (ENFN) Stock Price, News & Analysis

Company Overview

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois.

Key Stats

• Today's Range: $10.74 to $10.87
• 50-Day Range: $10.47 to $11.18
• 52-Week Range: $7.83 to $11.80
• Volume: 2.46 million shs
• Average Volume: 659,333 shs
• Market Capitalization: $1.40 billion
• P/E Ratio: 271.29
• Dividend Yield: N/A
• Price Target: $12.25
• Consensus Rating: Hold

ENFN Stock Analysis - Frequently Asked Questions

How have ENFN shares performed this year?

Enfusion's stock was trading at $10.30 at the beginning of 2025. Since then, ENFN shares have increased by 5.3% and is now trading at $10.8490.
View the best growth stocks for 2025 here.

How were Enfusion's earnings last quarter?

Enfusion, Inc. (NYSE:ENFN) issued its quarterly earnings results on Monday, March, 3rd. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by $0.02. The business had revenue of $52.94 million for the quarter, compared to analysts' expectations of $53.98 million. Enfusion had a trailing twelve-month return on equity of 6.67% and a net margin of 1.70%.

When did Enfusion IPO?

Enfusion (ENFN) raised $300 million in an initial public offering on Thursday, October 21st 2021. The company issued 18,750,000 shares at $15.00-$17.00 per share.

Who are Enfusion's major shareholders?

Top institutional investors of Enfusion include Vanguard Group Inc. (2.77%), Alpine Associates Management Inc. (1.89%), Trium Capital LLP (1.35%) and Nexpoint Asset Management L.P. (0.68%). Insiders that own company stock include Neal Pawar, Oleg Movchan, Bradley Herring, Bronwen Bastone, Dan Groman, Matthew Campobasso, Valeria Gutowski, Deirdre Somers, Tarek Hammoud and Stephen Malherbe.
View institutional ownership trends.

How do I buy shares of Enfusion?

Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Enfusion own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Enfusion investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 3/03/2025
• Today: 5/20/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Computer and Technology
• Industry: Prepackaged software
• Sub-Industry: Computer Software
• Current Symbol: NYSE:ENFN
• CIK: 1868912
• Web: www.enfusion.com
• Phone: 312-253-9800
• Fax: N/A
• Employees: 890
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $12.25
• High Stock Price Target: $13.00
• Low Stock Price Target: $11.50
• Potential Upside/Downside: +12.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.03
• Trailing P/E Ratio: 271.29
• Forward P/E Ratio: 180.82
• P/E Growth: 1.85
• Net Income: $6.03 million
• Net Margins: 1.70%
• Pretax Margin: 3.64%
• Return on Equity: 6.67%
• Return on Assets: 4.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.62
• Quick Ratio: 3.62

Sales & Book Value

• Annual Sales: $201.61 million
• Price / Sales: 6.94
• Cash Flow: $0.14 per share
• Price / Cash Flow: 78.75
• Book Value: $0.61 per share
• Price / Book: 17.79

Miscellaneous

• Outstanding Shares: 129,001,000
• Free Float: 81,720,000
• Market Cap: $1.40 billion
• Optionable: Optionable
• Beta: 0.92